Cell Therapy News/Articles, page-11591

IMO,

the smart thing would be to initiate an all cause ARDS trial and get data on that, then if it is successful and can get approval go on to try and get it approved for covid ARDS.

Continue focusing on further trials for heart failure and CLBP (though I am very skeptical about its use in CLBP).

I want to see a trial on infusions targeting heart failure rather than intracardiac injections. If the mechanism involved the cells targeting to sites of inflammation, why the need to inject directly. That's a much more invasive procedure and will be much more difficult to market.

I want to see a trial on infusing these cells into patients who have recently had an MI, it's the weeks following where a huge amount of inflammation and pathological remodelling occurs, this could be an ideal time to treat them, rather than later down the tract.

There's some serious potential. But putting so many eggs in this basket full of covid hype is very short sighted.